Tatva Chintan Pharma Chem Q1 FY27 Net Profit Zooms 140.3% YoY to ₹15.98 Crore

Specialty chemical manufacturer Tatva Chintan Pharma Chem Limited (NSE: TATVA; BSE: 543321) today announced its consolidated unaudited financial results for the first quarter of fiscal year 2026-27 (Q1 FY27). The company recorded an outstanding performance, posting a multi-fold expansion in bottom-line profits along with a double-digit top-line surge, backed by strong volume recovery and robust operational performance.

For the quarter ended June 30, 2026, the company's consolidated net profit stood at ₹159.81 million (₹15.98 crore). This reflects an exceptional year-on-year (YoY) increase of 140.3% compared to the ₹66.51 million (₹6.65 crore) reported in the corresponding first quarter of the previous fiscal year (Q1 FY26). Sequentially, net profit accelerated by 54.8% from the ₹103.21 million (₹10.32 crore) booked during the fourth quarter ended March 31, 2026 (Q4 FY26).

Robust Top-Line Performance Crosses ₹167 Crore

The structural rebound across specialty chemicals, structure-directing agents (SDAs), and green pharmaceutical intermediates provided substantial operational tailwinds:

Revenue from Operations: Consolidated revenue from operations for Q1 FY27 jumped 42.9% to ₹1,670.55 million (₹167.06 crore), up from ₹1,168.64 million recorded in Q1 FY26.

Total Income: Factoring in other income of ₹27.80 million (up from ₹11.55 million year-on-year), aggregate consolidated top-line revenue closed the initial quarter at ₹1,698.35 million against ₹1,180.19 million in Q1 FY26.

Expense Analysis & Inventory Build-Up

Total expenditures for the quarter under review stood at ₹1,474.06 million, compared to ₹1,089.18 million in the year-ago base quarter. Key cost segments included:

Raw Material Consumed: Sourcing and direct input costs expanded to ₹1,054.07 million, up from ₹638.89 million in Q1 FY26, in line with increased order fulfillment.

Inventory Adjustments: Strong manufacturing run-rates led to a considerable inventory addition adjustment of ₹(315.19) million, balancing finished goods and work-in-progress requirements.

Personnel & Administrative Costs: Employee benefits expenses rose moderately to ₹167.36 million against ₹140.86 million year-on-year. Other general administrative expenses stood at ₹427.32 million versus ₹271.02 million.

Finance & Capital Charges: Finance costs reached ₹20.81 million (up from ₹4.13 million in Q1 FY26), while depreciation expenses were logged at ₹105.66 million against ₹89.71 million.

The company encountered a one-time exceptional expense item of ₹13.18 million during the quarter. Despite this, profit before tax (PBT) reached ₹211.11 million, jumping 132.0% over the ₹91.01 million print in Q1 FY26. Total tax outgo comprised a current tax of ₹10.10 million and a deferred tax charge of ₹41.20 million.

Earnings Per Share (EPS): Backed by a strong absolute expansion in earnings capacity, the basic and diluted Earning Per Share (non-annualized) for Q1 FY27 rose to ₹6.83, showcasing a massive jump from ₹2.84 in Q1 FY26 and ₹4.41 sequentially in Q4 FY26.

Equity Share Base: The paid-up equity share capital of the company remained steady at ₹233.92 million (representing equity shares with a standard face value of ₹10 each).

Shares of Tatva Chintan Pharma Chem Ltd was last trading in BSE at Rs. 1428.45 as compared to the previous close of Rs. 1416.40. The total number of shares traded during the day was 5893 in over 521 trades.

The stock hit an intraday high of Rs. 1455.25 and intraday low of 1385.25. The net turnover during the day was Rs. 8373599.00.

Source : Equity Bulls

Keywords

TatvaChintanPharmaChem INE0GK401011 SpecialtyChemicals TATVA Q1FY27 Q1FY2027 ResultUpdate